Amplia has released its Quarterly Activities and Cash Flow Report for the quarter ended 31 March.
Key highlights for the quarter include:
- Review of available data from patients in Cohort 1 of the ACCENT trial of AMP945 in pancreatic cancer, concluded that dose escalation to a further cohort was appropriate
- Recruitment of three patients into Cohort 2 of the ACCENT trial
- Presentations of data from preclinical and clinical studies of AMP945 in pancreatic cancer presented at two high-profile cancer conferences
Amplia now has seven trial sites across Melbourne, Sydney and Brisbane, and progress has been made on a regulatory submission to open sites in South Korea.
Over the coming quarter, the Company expects to report further progress in the ACCENT trial as we finalise dose selection for the Phase 2 portion of the trial.
Read today’s ASX release.
